670 related articles for article (PubMed ID: 27503208)
1. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
2. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
4. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
5. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
[TBL] [Abstract][Full Text] [Related]
6. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
8. Clonality of CD4
Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
Front Immunol; 2019; 10():1336. PubMed ID: 31275310
[TBL] [Abstract][Full Text] [Related]
9. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
10. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
[TBL] [Abstract][Full Text] [Related]
11. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
12. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
13. Adoptive cell therapy using PD-1
Jing W; Gershan JA; Blitzer GC; Palen K; Weber J; McOlash L; Riese M; Johnson BD
J Immunother Cancer; 2017; 5():51. PubMed ID: 28642819
[TBL] [Abstract][Full Text] [Related]
14. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
15. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E
Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272
[TBL] [Abstract][Full Text] [Related]
16. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
Redmond WL; Gough MJ; Weinberg AD
Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
Martínez-Usatorre A; Donda A; Zehn D; Romero P
J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
[TBL] [Abstract][Full Text] [Related]
18. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
19. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
20. Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.
Polesso F; Weinberg AD; Moran AE
Cancer Immunol Res; 2019 Feb; 7(2):269-281. PubMed ID: 30563828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
